ANDA 212162, held by Eugia Pharma. Voriconazole.
As of Nov 21, 2026, ANDA 212162 (Voriconazole), held by Eugia Pharma, was first approved by FDA on Feb 2, 2023, with 0 approved supplements and 0 published complete response letters.
Voriconazole for injection is an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: Invasive aspergillosis Candidemia in non-neutropenics and other deep tissue Candida infections Esophageal candidiasis Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani, in patients intolerant of, or refractory to, other therapy 1.1 Invasive Aspergillosis Voriconazole for injection is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 2, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Voriconazole200MG/VIAL · powder;intravenous | Voriconazole | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters